The firm plans to use the proceeds to support commercial expansion in the US and EU, and for research, potential regulatory submissions, and general corporate purposes.

Sera Prognostics, Inc., The Pregnancy Company® ("Sera" or the "Company") (Nasdaq: SERA), which focuses on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,

Sera Prognostics (SERA) announced that it has commenced a proposed underwritten public offering of its Class A common stock and, in lieu of

Sera Prognostics, a company specializing in high-value women's health diagnostics with a market capitalization of $134 million, has seen its stock price touch a 52-week low, trading at $3.84. According to InvestingPro data,